Historical collection · First published Nov 13, 2024; added to EM Weekly Oct 27, 2026. This retrospective summary may be superseded by later evidence or guidance.
← All articlesUpdate on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association
Summary
This 2024 AHA scientific statement updates the 2017 Kawasaki disease guidance on diagnosis, risk stratification, acute treatment, coronary imaging, thromboprophylaxis, and long-term management. Diagnostic criteria remain clinical, while the update emphasizes early diagnosis, consistent coronary Z-score assessment, and identification of high-risk patients; the AHA summary identifies age 6 months or younger or baseline LAD/RCA Z-score at least 2.5 as high-risk features. For high-risk patients, IVIG plus intensified anti-inflammatory therapy is increasingly supported rather than IVIG alone, with treatment and follow-up coordinated by Kawasaki disease experts.
Why it matters
For the ED, prolonged unexplained fever with compatible mucocutaneous findings or incomplete Kawasaki features should trigger early laboratory evaluation, echocardiography/cardiology involvement, and timely IVIG-based treatment rather than waiting for every classic feature to appear. High-risk infants or patients with early coronary dilation may need intensified initial therapy and closer echo surveillance, while corrected thromboprophylaxis details should be managed with pediatric cardiology/Kawasaki expertise.
Study at a glance
- Design
- Consensus statement
- Population
- Children with suspected or confirmed Kawasaki disease, including incomplete presentations and patients at risk for or with coronary artery abnormalities.
- Sample size
- Not applicable
- Intervention
- Updated AHA recommendations for diagnosis, coronary risk stratification and imaging, IVIG-based acute therapy with intensified anti-inflammatory treatment for selected high-risk patients, and thromboprophylaxis and long-term management of coronary involvement.
- Comparator
- The 2017 AHA Kawasaki disease scientific statement and prior practice; this update is not a comparative trial.
- Primary endpoint
- Evidence synthesis and expert guidance for diagnosis, acute treatment, coronary imaging, thromboprophylaxis, and longitudinal management of Kawasaki disease; there is no trial primary endpoint.
Main findings
- Kawasaki disease remains a clinical diagnosis, and early recognition is emphasized to reduce coronary artery aneurysm risk; the diagnostic classification is unchanged from the 2017 statement.
- The AHA summary identifies age 6 months or younger or baseline LAD/RCA Z-score at least 2.5 as high-risk features, and increasingly supports IVIG plus intensified anti-inflammatory therapy for high-risk patients.
- The February 24, 2025 publisher correction changed long-term anticoagulation language: anticoagulation may be considered for risk level 5.2 when a large/giant aneurysm has regressed to medium and thrombosis risk persists, while anticoagulation is not indicated for risk level 5.3 when it has regressed to small; the correction also clarified that treatment intensification applies to IVIG-resistant or high-risk patients.
- The March 31, 2025 publisher correction changed a Figure 1 diagnostic-criteria item from a sub-bullet to a regular bullet; it did not introduce a new treatment recommendation.
Limitations
This is an AHA scientific statement, not a randomized trial, and several treatment recommendations rely on observational data, extrapolation, or expert consensus. A February 2025 correction materially changed anticoagulation and treatment-table language, and a March 2025 correction fixed Figure 1 formatting; this historical record incorporates those corrections but does not replace current specialist guidance.
Recommendation strength
American Heart Association scientific statement based on literature review and expert consensus; recommendations are not presented as one uniform GRADE-rated set.
Read the primary source
Full text: Official PDF available.
Original source Official source PDFDOI: 10.1161/CIR.0000000000001295
PMID: 39534969
Material reviewed: official society summary. Latest correction: Mar 31, 2025.
Source retrieved Oct 27, 2026. Historical backfill. PubMed and the American Heart Association Professional Heart Daily summary were reviewed and verify first-online publication on 2024-11-13, DOI 10.1161/CIR.0000000000001295, and PMID 39534969. Two official 2025 publisher corrections were reconciled: DOI 10.1161/CIR.0000000000001313 (article date 2025-02-24) changed anticoagulation and treatment-table language, and DOI 10.1161/CIR.0000000000001324 (Epub 2025-03-31) corrected Figure 1 bullet formatting. The hosted browser could retrieve publisher correction text but PDF screenshot rendering failed with a 403/cache error; the original statement PDF was not reviewed end-to-end, so reviewedMaterial remains official society summary rather than full text.
Corrections & review history
Feb 24, 2025 — Publisher correction DOI 10.1161/CIR.0000000000001313 revised Table 2 anticoagulation language for regressed large/giant coronary aneurysms, added a thrombosis-risk footnote, and clarified Table 3 treatment-intensification and aspirin-related text.
Mar 31, 2025 — Publisher correction DOI 10.1161/CIR.0000000000001324 corrected Figure 1 by changing the palmar/plantar erythema criterion from a sub-bullet to a regular bullet; no new treatment recommendation was introduced by this correction.